Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 58,750 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 58,750 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the sale, the chief operating officer now directly owns 630,166 shares in the company, valued at approximately $13,258,692.64. This trade represents a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Monday, October 7th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.57, for a total transaction of $1,149,737.50.
• On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total value of $172,122.85.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $21.80 on Thursday. The business’s fifty day moving average is $20.21 and its 200 day moving average is $19.09. The stock has a market capitalization of $4.76 billion, a PE ratio of 49.55 and a beta of 1.06. Hims & Hers Health, Inc. has a one year low of $7.51 and a one year high of $30.44.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC grew its holdings in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC grew its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the second quarter worth approximately $111,000. Finally, Quarry LP boosted its stake in shares of Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after acquiring an additional 2,913 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HIMS. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.